ERBB2 and breast carcinoma: SG is also being investigated in the adjuvant SASCIA clinical trial among patients with HER2-negative breast cancers with residual disease after neoadjuvant chemotherapy as compared to the physician’s choice (either capecitabine, platinum-based chemotherapy or observation) [39].